NantKwest Inc., part of billionaire Patrick Soon-Shiong’s biotech empire, has launched a clinical trial for its immunotherapy treatment that employs “natural killer cells” to combat cancer.
The company, which is headquartered at Soon-Shiong’s corporate campus in Culver City and has operations in San Diego, announced this week that it had entered a Phase 1 clinical study to determine the safety of its “haNK cell therapy” for up to 16 patients with various types of tumors. It also hoped to determine patient outcomes.
NantKwest, in which Soon-Shiong controls a 64 percent stake, focuses on harnessing the body’s immune system using the killer cells to treat cancer, inflammatory and infectious diseases.
Soon-Shiong, its president and chief executive, said only a tenth of people are born with a cell that, in combination with certain drugs, can kill cancer. He said his haNK cell therapy would help patient outcomes for “a significant percentage” of the remaining 90 percent.
NantKwest shares fell 4.2 percent on Tuesday to close an $5.45 Tuesday, a day after the clinical trial announcement.
Health business reporter Dana Bartholomew can be reached at firstname.lastname@example.org. Follow him on Twitter @_DanaBart.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- NantKWest Raises $39 Million From Company Founder Patrick Soon-Shiong
- Biotech Mogul Patrick Soon-Shiong to Launch Nant IPO
- Soon-Shiong’s NantKwest Goes Public in $207 Million Offering
- Soon-Shiong Plans Nant IPO
- Immunotherapy Developer Could Use Shot in Arm
- Soon-Shiong’s NantCell Acquires Italian Stem Cell Firm
- Shares Soar for Soon-Shiong Companies
- Soon-Shiong Pledges Manufacturing Here